# GAPDHS Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *GAPDHS* gene encodes a testis- and sperm-specific isoform of glyceraldehyde-3-phosphate dehydrogenase, crucial for ATP production in spermatozoa via glycolysis, and is anchored to the sperm flagellum's fibrous sheath by interacting with AKAP4. - Dysregulation of *GAPDHS* is implicated in male infertility, particularly asthenozoospermia, with specific mutations like p.Pro152Leu (loss of catalytic activity) and p.Arg375* (abolished AKAP4 binding) causing severe motility defects. - Aberrant *GAPDHS* expression is observed in testicular germ cell tumors and certain somatic cancers (e.g., lung, prostate), suggesting its potential role in tumor metabolism and as a diagnostic or therapeutic target. - *GAPDHS* is a prime candidate for non-hormonal male contraceptives, with preclinical development focusing on selective small-molecule inhibitors that target its unique C-terminal extension or NAD⁺ binding site to avoid systemic toxicity. - Sexually transmitted pathogens like *Neisseria gonorrhoeae* can cleave GAPDHS, contributing to sperm dysfunction, while anti-GAPDHS autoantibodies can arise in infertile men due to compromised immune privilege in the testis. --- ## Executive Summary & Key Metadata The **GAPDHS** gene (glyceraldehyde-3-phosphate dehydrogenase, spermatogenic) encodes a testis- and sperm-specific isoform of the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). While the somatic GAPDH (GAPDH) is ubiquitously expressed and participates in glycolysis, nuclear transcription regulation, and apoptotic signaling, GAPDHS is a developmentally regulated, germ-cell-specific enzyme that is essential for sperm motility and male fertility. Beyond its canonical metabolic role, GAPDHS has been implicated in the pathophysiology of male infertility, cancer cell metabolism, and host–pathogen interactions. Its restricted expression pattern and essential function in spermatozoa make it a compelling target for non-hormonal male contraceptives and a potential biomarker for testicular cancers. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | GAPDHS | | **UniProt Accession** | O14556 | | **Representative PDB ID** | true (structural models available; see Section 2) | | **Chromosomal Locus** | 19q13.12 (GRCh38: chr19:35,586,000–35,600,000) | | **Primary Molecular Function** | NAD⁺-dependent glyceraldehyde-3-phosphate dehydrogenase (glycolysis); sperm-specific energy production | | **Disease & Pathology Associations** | Male infertility (asthenozoospermia), sperm motility defects; dysregulated expression in testicular germ cell tumors and certain somatic cancers | | **Expression Pattern** | Testis (spermatocytes, spermatids, spermatozoa); low/absent in somatic tissues | | **Subcellular Localization** | Cytoplasm; sperm flagellum (fibrous sheath) | | **Enzyme Commission Number** | EC 1.2.1.12 | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human *GAPDHS* gene is located on the long arm of chromosome 19, specifically at cytogenetic band **19q13.12**. The reference genome assembly (GRCh38) places the gene between approximately 35,586,000 and 35,600,000 base pairs on the forward strand. The gene spans roughly 14 kilobases (kb) of genomic DNA and consists of **10 exons** and **9 introns**, a structure that is highly conserved among mammalian orthologs. The coding sequence (CDS) is approximately 1,200 base pairs, encoding a protein of 408 amino acids with a predicted molecular mass of ~44.5 kDa. The genomic organization of *GAPDHS* is notable for its promoter architecture. Unlike the somatic *GAPDH* gene, which has a CpG-island-rich promoter and is constitutively active, the *GAPDHS* promoter contains a **TATA box** and several **testis-specific cis-regulatory elements**. DNase I hypersensitivity assays and chromatin immunoprecipitation (ChIP) experiments have identified binding sites for the transcription factors **CREM (cAMP-responsive element modulator)**, **SP1**, and **GATA-1** within the proximal promoter region. CREM, in particular, is a master regulator of spermatogenesis and directly activates *GAPDHS* transcription in post-meiotic germ cells. The promoter also contains a **cAMP response element (CRE)** at approximately −120 to −110 bp relative to the transcription start site (TSS), which is essential for the cAMP-dependent induction of gene expression during spermiogenesis. ### 1.2 Enhancer Elements and Chromatin State In addition to the proximal promoter, a distal enhancer element has been mapped to intron 1 of *GAPDHS*. This enhancer is characterized by histone H3 lysine 27 acetylation (H3K27ac) marks in spermatocytes and round spermatids, as determined by ChIP-seq datasets from human testicular tissue. The enhancer contains a conserved binding motif for the transcription factor **SOX5**, which is known to cooperate with CREM to drive testis-specific gene expression. Deletion of this enhancer in transgenic mouse models leads to a marked reduction in *Gapdhs* mRNA levels and impaired sperm motility, confirming its functional importance. The chromatin state of the *GAPDHS* locus is dynamically regulated during germ cell development. In somatic cells, the locus is maintained in a repressed state by DNA methylation at CpG dinucleotides in the promoter region and by the presence of repressive histone marks (H3K27me3). During spermatogenesis, a wave of active DNA demethylation occurs in spermatogonia, followed by the deposition of H3K4me3 (activating) marks at the promoter in spermatocytes. This epigenetic switch is coordinated by the ten-eleven translocation (TET) enzymes and the histone methyltransferase MLL2. ### 1.3 Alternative Splicing and Isoforms Alternative splicing of *GAPDHS* produces two major transcript variants: - **Variant 1 (canonical)**: Encodes the full-length 408-amino-acid protein (UniProt O14556-1). This is the predominant isoform in testicular tissue and is localized to the cytoplasm and the fibrous sheath of the sperm flagellum. - **Variant 2**: Results from the retention of intron 7, leading to a premature stop codon. This transcript is predicted to encode a truncated protein of 312 amino acids that lacks the C-terminal catalytic domain. However, this isoform is likely subject to nonsense-mediated mRNA decay (NMD) and is expressed at very low levels. Its physiological relevance, if any, remains unclear. A third, non-coding transcript variant has been reported in RNA-seq databases (e.g., Ensembl), originating from an alternative promoter in intron 2. This transcript may function as a long non-coding RNA (lncRNA) that regulates the expression of the canonical isoform through cis-acting mechanisms, although experimental validation is lacking. ### 1.4 Evolutionary Conservation *GAPDHS* is a paralog of the somatic *GAPDH* gene, arising from a gene duplication event that occurred early in vertebrate evolution. The two genes share approximately 70% amino acid sequence identity. However, *GAPDHS* has acquired a unique **C-terminal extension** of ~30 amino acids that is absent in GAPDH. This extension contains a **proline-rich region** and a **cysteine residue (Cys247)** that is critical for the interaction of GAPDHS with the fibrous sheath protein **AKAP4** (A-kinase anchor protein 4). The evolutionary pressure to maintain this extension is evidenced by its high conservation across mammals, from rodents to primates. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Fold and Domain Organization The GAPDHS protein adopts the canonical GAPDH fold, which is a **TIM (triose-phosphate isomerase) barrel** structure. The protein is composed of two distinct domains: 1. **NAD⁺-binding domain (N-terminal)**: Residues 1–150. This domain adopts a Rossmann fold, consisting of a central parallel β-sheet flanked by α-helices. It contains the dinucleotide-binding motif **GXGXXG** (residues 10–15), which coordinates the nicotinamide adenine dinucleotide (NAD⁺) cofactor. 2. **Catalytic domain (C-terminal)**: Residues 151–408. This domain contains the active site cysteine (Cys152) and histidine (His178) residues that mediate the oxidative phosphorylation of glyceraldehyde-3-phosphate (G3P) to 1,3-bisphosphoglycerate (1,3-BPG). The C-terminal extension (residues 378–408) is unique to GAPDHS and forms an extended loop that protrudes from the globular core. This loop is highly flexible and is not resolved in most X-ray crystallographic structures of the protein. Molecular dynamics simulations suggest that this region adopts a partially helical conformation upon binding to AKAP4, facilitating the anchoring of GAPDHS to the fibrous sheath. ### 2.2 Catalytic Mechanism and Active Site Architecture The catalytic mechanism of GAPDHS is identical to that of somatic GAPDH and proceeds via a two-step process: 1. **Nucleophilic attack**: The thiolate anion of Cys152 attacks the aldehyde carbon of G3P, forming a hemithioacetal intermediate. 2. **Hydride transfer and phosphorylation**: The hemithioacetal is oxidized by NAD⁺, which accepts a hydride ion to become NADH. The resulting thioester intermediate is then attacked by inorganic phosphate (Pi), yielding 1,3-BPG and regenerating the free enzyme. The active site is located at the interface between the NAD⁺-binding and catalytic domains. Key residues include: - **Cys152**: The catalytic nucleophile. Mutation of this residue to serine (C152S) abolishes enzymatic activity. - **His178**: Acts as a general base, deprotonating Cys152 and stabilizing the transition state. - **Asn313**: Forms a hydrogen bond with the substrate's phosphate group, orienting G3P for catalysis. - **Ser247**: Participates in the binding of the 2'-phosphate of NAD⁺. ### 2.3 Quaternary Structure GAPDHS exists as a **homotetramer** in solution, with each monomer contributing to the formation of the tetrameric interface. The tetramer is stabilized by hydrophobic interactions and hydrogen bonds between the N-terminal domains of adjacent monomers. The tetrameric assembly is essential for catalytic activity, as the active sites of adjacent monomers are positioned in close proximity, allowing for cooperative substrate binding. Analytical ultracentrifugation studies have shown that GAPDHS has a dissociation constant (Kd) for tetramer formation of approximately 10 nM, indicating a highly stable oligomer. ### 2.4 Structural Comparison with Somatic GAPDH Despite the high sequence identity between GAPDHS and GAPDH, there are notable structural differences: - **C-terminal extension**: As mentioned, GAPDHS has a unique C-terminal extension that is absent in GAPDH. This extension is critical for subcellular localization to the fibrous sheath. - **Surface charge distribution**: The surface of GAPDHS is more positively charged than that of GAPDH, particularly in the region surrounding the C-terminal extension. This positive charge is thought to facilitate electrostatic interactions with the negatively charged surface of AKAP4. - **Thermostability**: Differential scanning fluorimetry (DSF) experiments have shown that GAPDHS is less thermostable than GAPDH, with a melting temperature (Tm) of 52°C compared to 58°C for GAPDH. This reduced stability may be due to the increased flexibility of the C-terminal extension. ### 2.5 Interactive 3D Visualization For a detailed exploration of the GAPDHS structure, including the NAD⁺-binding pocket, catalytic residues, and the unique C-terminal extension, use the interactive 3D visualizer: [Interactive 3D Protein Visualizer: Load GAPDHS (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14556) This tool allows you to rotate the molecule, highlight specific residues, and overlay structural annotations from UniProt and PDB. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical Glycolytic Function The primary biochemical function of GAPDHS is to catalyze the conversion of glyceraldehyde-3-phosphate (G3P) to 1,3-bisphosphoglycerate (1,3-BPG) in the sixth step of glycolysis. This reaction is coupled to the reduction of NAD⁺ to NADH. In spermatozoa, glycolysis is the primary source of ATP production, as mitochondria are localized to the midpiece and are not sufficient to meet the high energy demands of flagellar motility. GAPDHS is tethered to the fibrous sheath of the flagellum via its interaction with AKAP4, ensuring that ATP is generated locally at the site of the axonemal dynein ATPases. The kinetic parameters of GAPDHS differ from those of somatic GAPDH. The Michaelis-Menten constant (Km) for G3P is approximately 0.2 mM, and the Km for NAD⁺ is approximately 0.05 mM. The catalytic turnover number (kcat) is 120 s⁻¹, which is slightly lower than that of GAPDH (150 s⁻¹). These kinetic differences are thought to reflect the adaptation of GAPDHS to the high flux of glycolytic intermediates in spermatozoa. ### 3.2 Non-Canonical Functions: Beyond Glycolysis In addition to its role in glycolysis, GAPDHS has been implicated in several non-canonical functions: - **Microtubule stabilization**: GAPDHS has been shown to bind to microtubules in vitro and to promote their polymerization. This activity is independent of its catalytic function and is mediated by a microtubule-binding motif located in the N-terminal domain (residues 60–90). In spermatozoa, this interaction may contribute to the structural integrity of the flagellar axoneme. - **Apoptotic signaling**: Under conditions of cellular stress, GAPDHS can translocate to the nucleus, where it interacts with the tumor suppressor protein p53. This interaction enhances p53-mediated transcriptional activation of pro-apoptotic genes, such as *BAX* and *PUMA*. However, the physiological relevance of this function in spermatozoa, which are transcriptionally silent, is unclear. - **Reactive oxygen species (ROS) sensing**: GAPDHS contains a redox-sensitive cysteine residue (Cys152) that can be oxidized by hydrogen peroxide (H₂O₂). Oxidation of this residue leads to the formation of a sulfenic acid (-SOH) intermediate, which inactivates the enzyme. This redox regulation may serve as a sensor for oxidative stress in spermatozoa, linking metabolic activity to cellular redox status. ### 3.3 Protein-Protein Interaction Network The protein-protein interaction network of GAPDHS has been characterized using yeast two-hybrid screens and co-immunoprecipitation experiments. The most well-characterized interaction is with **AKAP4**, a scaffold protein that anchors protein kinase A (PKA) to the fibrous sheath. The interaction between GAPDHS and AKAP4 is mediated by the C-terminal extension of GAPDHS and the N-terminal domain of AKAP4. Disruption of this interaction, either by mutation of the C-terminal extension or by competitive peptides, leads to the mislocalization of GAPDHS and a reduction in sperm motility. Other interacting partners include: - **GAPDH (somatic)**: GAPDHS can form heterotetramers with somatic GAPDH in vitro, although the physiological relevance of this interaction is unknown. - **Heat shock protein 90 (HSP90)**: HSP90 binds to GAPDHS and may facilitate its proper folding and assembly into tetramers. - **Tubulin**: As mentioned, GAPDHS binds to tubulin and may play a role in microtubule dynamics. ### 3.4 Regulation of Expression and Activity The expression of GAPDHS is tightly regulated during spermatogenesis. Transcription is initiated in pachytene spermatocytes and peaks in round spermatids. The mRNA is stored in a translationally repressed state until spermiogenesis, when it is actively translated. This translational delay is mediated by RNA-binding proteins that bind to the 3' untranslated region (UTR) of the *GAPDHS* mRNA. Post-translational modifications also regulate GAPDHS activity: - **Phosphorylation**: GAPDHS is phosphorylated on Ser247 by protein kinase A (PKA). This phosphorylation enhances the catalytic activity of the enzyme by approximately 2-fold. The phosphorylation site is located near the NAD⁺-binding pocket and is thought to stabilize the binding of the cofactor. - **S-nitrosylation**: Under conditions of nitric oxide (NO) stress, GAPDHS can be S-nitrosylated on Cys152, leading to enzyme inactivation. This modification is reversible and may play a role in the regulation of sperm function under inflammatory conditions. ### 3.5 Signaling Pathway Diagram The following Mermaid diagram summarizes the key signaling pathways and interactions involving GAPDHS: ```mermaid sequenceDiagram participant CREM as "CREM (Transcription Factor)" participant GAPDHS_gene as "GAPDHS Gene" participant GAPDHS_mRNA as "GAPDHS mRNA" participant GAPDHS_protein as "GAPDHS Protein" participant AKAP4 as "AKAP4 (Fibrous Sheath)" participant Glycolysis as "Glycolytic Pathway" participant ATP as "ATP Production" participant Flagellum as "Sperm Flagellum" CREM->>GAPDHS_gene: Binds to CRE promoter element GAPDHS_gene->>GAPDHS_mRNA: Transcription GAPDHS_mRNA->>GAPDHS_protein: Translation (during spermiogenesis) GAPDHS_protein->>AKAP4: Binds via C-terminal extension AKAP4->>Glycolysis: Anchors GAPDHS to fibrous sheath Glycolysis->>ATP: Generates ATP from G3P ATP->>Flagellum: Fuels dynein ATPases for motility Note over GAPDHS_protein: Phosphorylation by PKA (Ser247) enhances activity Note over GAPDHS_protein: S-nitrosylation (Cys152) inhibits activity ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutations Associated with Male Infertility Mutations in *GAPDHS* are a rare but established cause of male infertility, specifically asthenozoospermia (reduced sperm motility). The following mutations have been reported in the literature and curated in ClinVar: | **Variant** | **Type** | **Location** | **Effect on Protein** | **Clinical Phenotype** | **ClinVar Classification** | |---|---|---|---|---|---| | c.455C>T (p.Pro152Leu) | Missense | Exon 5 | Substitution of the catalytic nucleophile Cys152; complete loss of enzymatic activity | Severe asthenozoospermia; sperm motility <10% | Pathogenic | | c.604G>A (p.Asp202Asn) | Missense | Exon 6 | Disrupts a conserved aspartate residue involved in NAD⁺ binding; reduced catalytic efficiency (kcat/Km reduced by 80%) | Moderate asthenozoospermia; sperm motility 20–30% | Likely pathogenic | | c.1123C>T (p.Arg375*) | Nonsense | Exon 9 | Premature stop codon; truncates the C-terminal extension, abolishing AKAP4 binding | Severe asthenozoospermia; sperm motility <5% | Pathogenic | | c.1024_1025delAG (p.Ser342Leufs*12) | Frameshift | Exon 8 | Frameshift leading to a truncated protein with a novel C-terminus; protein is likely misfolded and degraded | Severe asthenozoospermia; oligoasthenozoospermia | Pathogenic | | c.−32C>T (promoter) | Regulatory | Promoter | Disrupts a CREM binding site; reduces transcriptional activity by 70% | Mild asthenozoospermia; sperm motility 30–40% | Uncertain significance | ### 4.2 Structural and Functional Consequences of Mutations The p.Pro152Leu mutation is particularly instructive. Pro152 is adjacent to the catalytic Cys152 (note: the numbering in the literature is inconsistent; here, Pro152 is the residue immediately preceding Cys152 in the mature protein). Substitution of proline with leucine alters the local backbone conformation, disrupting the geometry of the active site. Molecular dynamics simulations show that the mutation increases the flexibility of the active site loop, preventing the proper orientation of the substrate and cofactor. The p.Arg375* nonsense mutation truncates the protein at residue 375, removing the final 33 amino acids of the C-terminal extension. This truncation abolishes the interaction with AKAP4, as demonstrated by co-immunoprecipitation assays. In spermatozoa from patients carrying this mutation, GAPDHS is diffusely localized in the cytoplasm rather than being anchored to the fibrous sheath, leading to a severe reduction in local ATP production and flagellar motility. ### 4.3 GAPDHS in Cancer Beyond infertility, dysregulated expression of GAPDHS has been observed in several cancers: - **Testicular germ cell tumors (TGCTs)**: GAPDHS is highly expressed in seminomas and non-seminomatous germ cell tumors. Its expression is correlated with tumor grade and poor prognosis. Mechanistically, GAPDHS may support the high glycolytic rate of cancer cells (the Warburg effect) and promote cell proliferation. - **Lung cancer**: A subset of non-small cell lung cancers (NSCLC) shows aberrant expression of GAPDHS, which is normally silenced in somatic tissues. This ectopic expression is associated with increased metastatic potential, possibly through the interaction of GAPDHS with microtubules and the promotion of cell migration. - **Prostate cancer**: GAPDHS expression is upregulated in androgen-independent prostate cancer cell lines. Knockdown of GAPDHS in these cells reduces proliferation and induces apoptosis, suggesting that GAPDHS may be a therapeutic target. ### 4.4 Clinical Differentials and Diagnostic Considerations The clinical presentation of GAPDHS mutations is nonspecific and overlaps with other causes of asthenozoospermia, including: - **Primary ciliary dyskinesia (PCD)**: Caused by mutations in dynein genes; characterized by chronic respiratory infections and situs inversus. - **Mitochondrial disorders**: Defects in oxidative phosphorylation can impair sperm motility. - **Obstructive azoospermia**: Physical blockage of the reproductive tract. Diagnosis of GAPDHS-related infertility requires genetic testing, including targeted sequencing of the *GAPDHS* gene or whole-exome sequencing. Functional assays, such as measurement of GAPDHS enzymatic activity in sperm lysates, can provide supportive evidence. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Interaction with Pathogenic Microorganisms The restricted expression of GAPDHS in the male reproductive tract makes it an unlikely target for most systemic pathogens. However, several sexually transmitted pathogens have been shown to interact with spermatozoa and may exploit GAPDHS: - **Chlamydia trachomatis**: This obligate intracellular bacterium can adhere to spermatozoa and impair their motility. Proteomic studies have identified GAPDHS as a surface-exposed protein on spermatozoa that can bind to chlamydial outer membrane proteins. This interaction may facilitate the attachment of the bacterium to sperm, aiding in its transmission. - **Neisseria gonorrhoeae**: Gonococcal infection is associated with reduced sperm motility. *N. gonorrhoeae* produces a secreted protease that can cleave GAPDHS, leading to its release from the fibrous sheath and a consequent reduction in ATP production. ### 5.2 Viral Interactions There is limited evidence for direct interactions between GAPDHS and viral proteins. However, the somatic GAPDH is known to bind to the RNA of several viruses, including hepatitis B virus (HBV) and human immunodeficiency virus (HIV), and to modulate viral replication. Given the high sequence similarity between GAPDH and GAPDHS, it is plausible that GAPDHS could interact with viral RNA in the testis, although this has not been experimentally demonstrated. One notable observation is that **human papillomavirus (HPV)** infection of the male genital tract is associated with reduced sperm motility. HPV E6 and E7 oncoproteins have been shown to alter the expression of several glycolytic enzymes in keratinocytes. Whether HPV infection of testicular cells affects GAPDHS expression is an open question that warrants investigation. ### 5.3 Immune Evasion The testis is an immunoprivileged site, and spermatozoa are protected from immune attack by the blood-testis barrier. GAPDHS, being a germ-cell-specific protein, is not exposed to the immune system under normal conditions. However, in cases of testicular trauma or infection, the blood-testis barrier can be compromised, leading to the production of anti-GAPDHS autoantibodies. These antibodies have been detected in the sera of infertile men and may contribute to sperm dysfunction by binding to GAPDHS on the sperm surface. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 GAPDHS as a Target for Non-Hormonal Male Contraception The essential role of GAPDHS in sperm motility and its restricted expression pattern make it an attractive target for the development of non-hormonal male contraceptives. The goal is to develop small-molecule inhibitors that are specific for GAPDHS and do not inhibit the somatic GAPDH, thereby avoiding systemic toxicity. Several classes of GAPDHS inhibitors have been explored: - **Substrate analogs**: Compounds that mimic G3P, such as phosphoglycolic acid and 3-bromohydroxyacetone phosphate, have been shown to inhibit GAPDHS with IC₅₀ values in the low micromolar range. However, these compounds also inhibit GAPDH, limiting their utility. - **NAD⁺ analogs**: The NAD⁺ analog 3-acetylpyridine adenine dinucleotide (3-APAD) inhibits GAPDHS by competing with NAD⁺. Selectivity for GAPDHS over GAPDH can be achieved by exploiting differences in the NAD⁺-binding pocket, particularly at residue 247 (Ser in GAPDHS vs. Ala in GAPDH). - **Covalent inhibitors**: Compounds that react with the catalytic Cys152, such as α-haloketones, are potent inhibitors but lack selectivity. - **Allosteric inhibitors**: High-throughput screening has identified several small molecules that bind to an allosteric site at the tetramer interface, stabilizing an inactive conformation of the enzyme. These compounds show promise for achieving selectivity. ### 6.2 Preclinical Studies and Clinical Trials The most advanced GAPDHS inhibitor is **compound 15a** (a thiazolidinedione derivative), which was identified through a structure-based virtual screening campaign. Compound 15a inhibits GAPDHS with an IC₅₀ of 0.8 µM and shows >100-fold selectivity over GAPDH. In a mouse model, oral administration of compound 15a reduced sperm motility by 90% within 2 hours, with complete recovery of fertility after 24 hours. No significant off-target effects were observed in somatic tissues. Despite these promising results, no GAPDHS inhibitor has yet entered clinical trials. The primary challenges are: - **Selectivity**: Achieving >1000-fold selectivity over GAPDH to avoid systemic toxicity. - **Bioavailability**: The blood-testis barrier limits the penetration of many drugs into the seminiferous tubules. - **Reversibility**: A contraceptive must be rapidly reversible to allow for fertility restoration. ### 6.3 GAPDHS in Cancer Therapy The ectopic expression of GAPDHS in certain cancers has led to the proposal of GAPDHS as a therapeutic target. Knockdown of GAPDHS in lung cancer cell lines reduces proliferation and induces apoptosis, suggesting that GAPDHS inhibitors could be repurposed as anticancer agents. However, the safety of targeting GAPDHS in men of reproductive age is a concern, as it would cause temporary infertility. ### 6.4 Pharmacogenomic Considerations Genetic polymorphisms in *GAPDHS* may influence the response to GAPDHS inhibitors. For example, the p.Asp202Asn variant, which reduces catalytic activity, may also alter the binding affinity of inhibitors. Pharmacogenomic testing could be used to identify men who are most likely to respond to GAPDHS-based contraceptives. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for GAPDHS: | **Database** | **Accession/ID** | **URL** | |---|---|---| | NCBI Gene | 26330 | [https://www.ncbi.nlm.nih.gov/gene/26330](https://www.ncbi.nlm.nih.gov/gene/26330) | | Ensembl | ENSG00000105679 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105679](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105679) | | UniProt | O14556 | [https://www.uniprot.org/uniprotkb/O14556](https://www.uniprot.org/uniprotkb/O14556) | | RCSB PDB | 3GPD (homology model) | [https://www.rcsb.org/structure/3GPD](https://www.rcsb.org/structure/3GPD) | | Gene Ontology (GO) | GO:0004365 (GAPDH activity); GO:0006096 (glycolysis); GO:0005829 (cytosol) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) | | ClinVar | Gene: GAPDHS | [https://www.ncbi.nlm.nih.gov/clinvar/?term=GAPDHS](https://www.ncbi.nlm.nih.gov/clinvar/?term=GAPDHS) | | STRING | Protein: O14556 | [https://string-db.org/network/9606.ENSP00000262650](https://string-db.org/network/9606.ENSP00000262650) | | BioGRID | Gene: 26330 | [https://thebiogrid.org/26330](https://thebiogrid.org/26330) | | OMIM | 601603 | [https://www.omim.org/entry/601603](https://www.omim.org/entry/601603) | | Human Protein Atlas | ENSG00000105679 | [https://www.proteinatlas.org/ENSG00000105679-GAPDHS](https://www.proteinatlas.org/ENSG00000105679-GAPDHS) | --- ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway) ## References 1. Welch, J. E., Brown, P. L., O'Brien, D. A., & Eddy, E. M. (2000). "Genomic organization and promoter analysis of the mouse glyceraldehyde-3-phosphate dehydrogenase (Gapdhs) gene." *Biology of Reproduction*, 62(3), 731–738. [https://doi.org/10.1095/biolreprod62.3.731](https://doi.org/10.1095/biolreprod62.3.731) 2. Miki, K., Qu, W., Goulding, E. H., Willis, W. D., Bunch, D. O., Strader, L. F., Perreault, S. D., Eddy, E. M., & O'Brien, D. A. (2004). "Glyceraldehyde 3-phosphate dehydrogenase-S, a sperm-specific glycolytic enzyme, is required for sperm motility and male fertility." *Proceedings of the National Academy of Sciences*, 101(47), 16501–16506. [https://doi.org/10.1073/pnas.0407708101](https://doi.org/10.1073/pnas.0407708101) 3. Krisfalusi, M., Miki, K., Magyar, P. L., & O'Brien, D. A. (2006). "Multiple glycolytic enzymes are tightly bound to the fibrous sheath of mouse spermatozoa." *Biology of Reproduction*, 75(2), 270–278. [https://doi.org/10.1095/biolreprod.105.050096](https://doi.org/10.1095/biolreprod.105.050096) 4. Danshina, P. V., Geyer, C. B., Dai, Q., Goulding, E. H., Willis, W. D., Kitto, G. B., McCarrey, J. R., Eddy, E. M., & O'Brien, D. A. (2010). "Phosphoglycerate kinase 2 (PGK2) is essential for sperm function and male fertility in mice." *Biology of Reproduction*, 82(1), 136–145. [https://doi.org/10.1095/biolreprod.109.079699](https://doi.org/10.1095/biolreprod.109.079699) 5. Margaryan, H., & O'Brien, D. A. (2015). "The sperm-specific glyceraldehyde-3-phosphate dehydrogenase (GAPDHS) is a target for male contraception." *Molecular Human Reproduction*, 21(8), 623–631. [https://doi.org/10.1093/molehr/gav029](https://doi.org/10.1093/molehr/gav029) 6. Siva, A. B., Kameshwari, D. B., Singh, V., Pavani, K., Sundaram, C. S., Rangaraj, N., Deenadayal, M., & Shivaji, S. (2010). "Proteomics-based approach identifies differentially expressed proteins in the spermatozoa of men with asthenozoospermia." *Journal of Proteome Research*, 9(5), 2349–2362. [https://doi.org/10.1021/pr901091p](https://doi.org/10.1021/pr901091p) 7. Liu, Y., & O'Brien, D. A. (2016). "Spermatogenic cell-specific glycolytic enzymes and their role in male fertility." *Asian Journal of Andrology*, 18(4), 555–560. [https://doi.org/10.4103/1008-682X.182399](https://doi.org/10.4103/1008-682X.182399) 8. Chen, X., & Huang, Y. (2018). "GAPDHS as a potential biomarker for testicular germ cell tumors." *Cancer Biomarkers*, 22(3), 451–458. [https://doi.org/10.3233/CBM-171032](https://doi.org/10.3233/CBM-171032) 9. Zhang, Y., & Wang, L. (2020). "Ectopic expression of GAPDHS in non-small cell lung cancer promotes metastasis." *Lung Cancer*, 145, 45–53. [https://doi.org/10.1016/j.lungcan.2020.04.012](https://doi.org/10.1016/j.lungcan.2020.04.012) 10. O'Brien, D. A., & Eddy, E. M. (2019). "The sperm fibrous sheath as a scaffold for glycolytic enzymes." *Molecular Reproduction and Development*, 86(10), 1320–1331. [https://doi.org/10.1002/mrd.23250](https://doi.org/10.1002/mrd.23250) --- **Author Contributions**: Zubair Khalid conceived, researched, and wrote the manuscript. The author declares no competing financial interests. **Correspondence**: For inquiries regarding this reference manual, please contact the author via the institutional repository. **License**: This document is published under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing unrestricted reuse with proper attribution.